Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

Cardiovascular Diabetology

Volumn 7, Issue , 2008, Pages

  Farah, Raymond ^a   Shurtz Swirski, Revital ^b   Lapin, Olga ^b  

^a Rebecca Sieff Government Hospital   (Israel)

^b WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CD11B ANTIGEN; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PHORBOL ESTER; ROSIGLITAZONE; SUPEROXIDE; TRANSFERRIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM INJURY; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN BLOOD LEVEL; LEUKOCYTE COUNT; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; ANTIGENS, CD11B; APOPTOSIS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; LEUKOCYTES, MONONUCLEAR; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; SUPEROXIDES; THIAZOLIDINEDIONES; TRANSFERRIN;

EID: 46749148847     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-7-20     Document Type: Article

References (36)

1. Stern MP The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes Arch Fam Med 1998, 7(2):155-162. 10.1001/archfami.7.2.155 9519921
2. Medical management of type 2 diabetes American Diabetes Association 4, 1998:10-108.
3. Vogel RA Coronary risk factor, endothelial function, and aatherosclerosis: A review Clin Cardiol 1997, 20:426-432. 9134272
4. Laakso M Lehto S Epidemiology of macrovascular disease in diabetes Diabetes Rev 1997, 5:294-295.
5. Stehouwer CD Labmert J Donker AJ van Hinsbergh VW Endothelial dysfunction and pathogenesis of diabetic angipathy Cardiovasc Res 1997, 34:55-68. 10.1016/S0008-6363(96)00272-6 9217873
6. Pinkley J Stehouwer C coppack S Yudkin J Endothelial dysfunction: Cause of the insulin esistence syndrome Diabetes 1997, 46:S9-S13. 9285492
7. Kunitomo M Oxidative stress and atherosclerosis Yakugaku Zasshi 2007, 127:1997-2014. 10.1248/yakushi.127.1997 18057788
8. Gorter PM Visseren FL Algra A Graaf van der Y on behalf of the SMART Study Group The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study Diabet Med 2007, 24:1352-1360. 10.1111/j.1464-5491.2007.02323.x 18042079
9. Chapman MJ Metabolic syndrome and type 2 diabetes: Lipid and physiological consequences Diab Vasc Dis Res 2007, 4(Suppl 3):S5-8. 17935058
10. Nitenberg A Paycha F Ledoux S Sachs R Attali JR Valensi P Coronary artery responses to physiologic stimuli are impoved by desferoxamine but not by L-arginine on non-insulin-dependent diabetic patiens with angiographically normal coronary arteries and no other risk factors Circulation 1998, 97:736-743. 9498536
11. Wells-knecht KJ Brinkmann E Welle-Knecht Mc Litcfield JE Ahmed Mu Reddy S Zyzak DV Thorpe SR Baynes JW New biomarkers of Maillard reaction damage to proteins Nephrol Dial Transplant 1996, 11(suppl 5):41-47. 9044306
12. Sesni M Pricci F Andreani D Di Mario U Advanced nonenzymatic glycation endproducts (AGE): Their relevance to aging and the pathogenesis of late diabetic complications Diabetes Res 1991, 16:1-9. 1818791
13. Wolfenbuttel BHR Giordano D Founds HW Bucala R Long term assessment of glucose control by haemoglobin-AGE measurment Lancet 1996, 347:513-515. 10.1016/S0140-6736(96)91141-1 8596270
14. Kristal B Shurtz-Swirski R Shapiro G Chezar J Manaster J Shasha SM Sela S Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension Am J Hypertens 1998. 11:921-928. 10.1016/ S0895-7061(98)00099-5 9715783
15. Shurtz-Swirski R Sela S Shapiro G Nasser L Shasha SM Kristal B Involvement of polymorphonuclearleukocytes in oxidative stress and inflammation in type 2 diabetes Diabetes care 2001, 24:104-110. 10.2337/ diacare.24.1.104 11194213
16. Sela S Shurtz-Swirski R Cohen-Mazor M Mazor R Chezar J Shapiro G Hassan K Shkolnik G Geron R Kristal B The Primed Peripheral Polymorphonuclear Leukocyte - a Culprit Underlying Chronic Low-Grade Inflammation and Systemic Oxidative Stress in Chronic Kidney Disease J Am Soc Nephrol 2005, 16:2431-2438. 10.1681/ASN.2004110929 15987755
17. Tennenberg SD Finkenauer R Dwivedi A Absence of lipopolysaccaride-induced inhibition of neutrophil apoptosis in patients with diabetes Arch Surg 1999, 134:1229-1233. 10.1001/ archsurg.134.11.1229 10555638
18. Koenig W Khuseyinova N Hoffman MM Marz W Frohlich M Hoffmeister A Brenner H Rothenbacher D CD14 C(-260) → T Polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease J Clin Invest 1986, 77:1233-1243. 424465 3485659 10.1172/JCI112426 disease
19. Yasunari K Meada Nakamura M Yoshikawa J Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein Hypertension 2002, 39:777-780. 10.1161/hy0302.104670 11897762
20. Phillips M Cataneo N Renee Cheema T Greenberg J Increased breath biomarker of oxidative stress in diabetes mellitus Clin Chim Acta 2004, 334(1-2):189-194. 10.1016/j.cccn.2004.02.025
21. Huang A Raskin P Thiazolidinediones and insulin: Rationale for use and role of combination therapy in type 2 diabetes mellitus Treat Endocrinol 2005, 4:205-220. 10.2165/00024677-200504040-00002 16053338
22. Md Isa SH Najihah I Nazaimoon WM Kamarudin NA Umar NA Mat NH Khalid BA Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control Diabetes Res Clin Pract 2006, 72:48-52. 10.1016/ j.diabres.2005.09.011 16253380
23. Dandona P Aljada A Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents J Diabetes Complications 2004, 18:91-102. 10.1016/S1056-8727(02)00259-3 15120703
24. Bhansali A Modi P Thiazolidinediones in type 2 diabetes - have they lived up to expectations? J Indian Med Assoc 2005, 103:343-346. 16225162
25. Rosenberg DE Jabbour SA Goldstein BJ Insulin resistance, diabetes and cardiovascular risk: Approaches to treatment Diabetes Obes Metab 2005, 7:642-653. 10.1111/j.1463-1326.2004.00446.x 16219008
26. Klebanoff SJ Clark RA Iodination by human polymorphonuclear leukocytes J Lab Clin Med 1977, 89:675-686. 839126
27. Babior BM Kipnes RS Curnnute JJ Biological defence mechanism. The production by leukocytes of superoxide, a potential bactericidal agent J Clin Invest 1973, 52:741-744. 302313 4346473 10.1172/JCI107236
28. Swain SD Rohn TT Quinn MT Neutrophil priming in host defense: Role of oxidants as priming agents Antioxid Redox Signal 2002, 4:69-83. 10.1089/ 152308602753625870 11970845
29. Kuypers FA Lewis RA Hua M Schott MA Discher D Ernst JD Lubin BH Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled Annexin V Blood 1996, 87:1179-1187. 8562945
30. Palumbo PJ Metformin: Effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus J Diabetes Complications 1998, 12:110-119. 10.1016/S1056-8727(97)00053-6 9559489
31. Ajjan RA Grant PJ Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents Diab Vasc Dis Res 2006, 3:147-158. 10.3132/dvdr.2006.023 17160909
32. Onuta G Rienstra H de Boer JF Boer MW Roks AJ Klatter FA Uges DR Navis G Rozing J Hillebrands JL Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats Transplantation 2007, 84:517-526. 10.1097/01.tp.0000276983.91892.99 17713437
33. Pfützner A Weber MM Forst T Pioglitazone: Update on an oral antidiabetic drug with antiatherosclerotic effects Expert Opin Pharmacother 2007, 8:1985-1998. 10.1517/14656566.8.12.1985 17696799
34. Mazzone T Prevention of macrovascular disease in patients with diabetes mellitus: Opportunities for intervention Am J Med 2007, 120(9 Suppl 2):S26-32, 10.1016/j.amjmed.2007.07.005 17826043
35. Mittermayer F Schaller G Pleiner J Krzyzanowska K Kapiotis S Roden M Wolzt M Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction J Clin Endocrinol Metab 2007, 92:2574-2580. 10.1210/jc.2006-2130 17473072
36. Orio F Manguso F Di Biase S Falbo A Giallauria F Labella D Tolino A Lombardi G Colao A Palomba S Metformin administration improves leukocyte count in women with polycystic ovary syndrome: A 6-month prospective study Eur J Endocrinol 2007, 157:69-73. 10.1530/EJE-07-0133 17609404